Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients

Saved in:
Bibliographic Details
Published in:European Heart Journal - Cardiovascular Pharmacotherapy 2020-07, Vol.6 (3), p.135-136
Main Authors: Acanfora, Domenico, Ciccone, Marco Matteo, Scicchitano, Pietro, Acanfora, Chiara, Casucci, Gerardo
Format: Article
Language:English
Subjects:
Aminobutyrates
Angiotensin Receptor Antagonists
Animals
Antiviral agents
Apolipoproteins
Betacoronavirus
Coronavirus Infections
Coronaviruses
Correspondence
COVID-19
Drug Combinations
Health aspects
Humans
Inflammation
Mice
Neprilysin
Pandemics
Plaque, Atherosclerotic
Pneumonia, Viral
SARS Virus
SARS-CoV-2
Severe acute respiratory syndrome
Tetrazoles
Vaccines
Valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2055-6837
2055-6845
DOI:10.1093/ehjcvp/pvaa028